Spectacular efficiency of Tocilizumab in a refractory systemic form of adult-onset Still's disease: a case report
Contenu principal de l'article
Résumé
INTRODUCTION
Adult-onset still’s disease (AOSD) is a rare
systemic inflammatory disorder. Its treatment is
not based on controlled study, but on case based
experiences It combines corticosteroï ds and Méthotrexate (MTX).
fifty patients with refractory AOSD treated
with anti-IL-6 (Tocilizumab). We report a new
observation.
Details de l'article
Numéro
Rubrique
Cas rapportés